FGF-21 as a novel metabolic regulator

Alexei Kharitonenkov, Tatiyana L. Shiyanova, Anja Koester, Amy M. Ford, Radmila Micanovic, Elizabeth J. Galbreath, George Sandusky, Lisa J. Hammond, Julie S. Moyers, Rebecca A. Owens, Jesper Gromada, Joseph T. Brozinick, Eric D. Hawkins, Victor J. Wroblewski, De Shan Li, Farrokh Mehrbod, S. Richard Jaskunas, Armen B. Shanafelt

Research output: Contribution to journalArticle

1233 Citations (Scopus)

Abstract

Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)1627-1635
Number of pages9
JournalJournal of Clinical Investigation
Volume115
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Transgenic Mice
Glucose
Hypoglycemia
Adipocytes
Weight Gain
fibroblast growth factor 21
Diabetes Mellitus
Triglycerides
Therapeutics
Obesity
Diet
Health
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., ... Shanafelt, A. B. (2005). FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115(6), 1627-1635. https://doi.org/10.1172/JCI23606

FGF-21 as a novel metabolic regulator. / Kharitonenkov, Alexei; Shiyanova, Tatiyana L.; Koester, Anja; Ford, Amy M.; Micanovic, Radmila; Galbreath, Elizabeth J.; Sandusky, George; Hammond, Lisa J.; Moyers, Julie S.; Owens, Rebecca A.; Gromada, Jesper; Brozinick, Joseph T.; Hawkins, Eric D.; Wroblewski, Victor J.; Li, De Shan; Mehrbod, Farrokh; Jaskunas, S. Richard; Shanafelt, Armen B.

In: Journal of Clinical Investigation, Vol. 115, No. 6, 06.2005, p. 1627-1635.

Research output: Contribution to journalArticle

Kharitonenkov, A, Shiyanova, TL, Koester, A, Ford, AM, Micanovic, R, Galbreath, EJ, Sandusky, G, Hammond, LJ, Moyers, JS, Owens, RA, Gromada, J, Brozinick, JT, Hawkins, ED, Wroblewski, VJ, Li, DS, Mehrbod, F, Jaskunas, SR & Shanafelt, AB 2005, 'FGF-21 as a novel metabolic regulator', Journal of Clinical Investigation, vol. 115, no. 6, pp. 1627-1635. https://doi.org/10.1172/JCI23606
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation. 2005 Jun;115(6):1627-1635. https://doi.org/10.1172/JCI23606
Kharitonenkov, Alexei ; Shiyanova, Tatiyana L. ; Koester, Anja ; Ford, Amy M. ; Micanovic, Radmila ; Galbreath, Elizabeth J. ; Sandusky, George ; Hammond, Lisa J. ; Moyers, Julie S. ; Owens, Rebecca A. ; Gromada, Jesper ; Brozinick, Joseph T. ; Hawkins, Eric D. ; Wroblewski, Victor J. ; Li, De Shan ; Mehrbod, Farrokh ; Jaskunas, S. Richard ; Shanafelt, Armen B. / FGF-21 as a novel metabolic regulator. In: Journal of Clinical Investigation. 2005 ; Vol. 115, No. 6. pp. 1627-1635.
@article{1d10f5cdad564d94ba667ff1d35c6de5,
title = "FGF-21 as a novel metabolic regulator",
abstract = "Diabetes mellitus is a major health concern, affecting more than 5{\%} of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.",
author = "Alexei Kharitonenkov and Shiyanova, {Tatiyana L.} and Anja Koester and Ford, {Amy M.} and Radmila Micanovic and Galbreath, {Elizabeth J.} and George Sandusky and Hammond, {Lisa J.} and Moyers, {Julie S.} and Owens, {Rebecca A.} and Jesper Gromada and Brozinick, {Joseph T.} and Hawkins, {Eric D.} and Wroblewski, {Victor J.} and Li, {De Shan} and Farrokh Mehrbod and Jaskunas, {S. Richard} and Shanafelt, {Armen B.}",
year = "2005",
month = "6",
doi = "10.1172/JCI23606",
language = "English (US)",
volume = "115",
pages = "1627--1635",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - FGF-21 as a novel metabolic regulator

AU - Kharitonenkov, Alexei

AU - Shiyanova, Tatiyana L.

AU - Koester, Anja

AU - Ford, Amy M.

AU - Micanovic, Radmila

AU - Galbreath, Elizabeth J.

AU - Sandusky, George

AU - Hammond, Lisa J.

AU - Moyers, Julie S.

AU - Owens, Rebecca A.

AU - Gromada, Jesper

AU - Brozinick, Joseph T.

AU - Hawkins, Eric D.

AU - Wroblewski, Victor J.

AU - Li, De Shan

AU - Mehrbod, Farrokh

AU - Jaskunas, S. Richard

AU - Shanafelt, Armen B.

PY - 2005/6

Y1 - 2005/6

N2 - Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

AB - Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=20444435873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444435873&partnerID=8YFLogxK

U2 - 10.1172/JCI23606

DO - 10.1172/JCI23606

M3 - Article

C2 - 15902306

AN - SCOPUS:20444435873

VL - 115

SP - 1627

EP - 1635

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -